Senores Pharma Files Reconciliation of Share Capital Audit Report for Q4FY26
Senores Pharmaceuticals submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. All 4,60,53,588 shares are in dematerialized form. The company also noted the issuance of 11,70,000 warrants on March 28, 2026, and management changes effective March 17, 2026.
This is a standard compliance filing regarding share capital reconciliation and does not involve any significant new business developments, financial results, or corporate actions that would materially affect the company's operations or stock.
The announcement is a routine regulatory filing and does not contain any information that positively or negatively impacts the company's financial performance or outlook.
Senores Pharmaceuticals Limited has submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. The report, dated April 06, 2026, was issued by Mr. Tapan Shah, Company Secretary in Practice, in compliance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
The company's issued equity share capital stands at 4,60,53,588 shares. As of March 31, 2026, all shares were held in dematerialized form, with 2,91,61,082 shares (63.32%) held in NSDL and 1,68,92,506 shares (36.68%) held in CDSL. There were no shares held in physical form, and the register of members has been updated.
The report also notes the issuance of 11,70,000 convertible equity warrants on a preferential basis to promoter and promoter group categories, with allotment completed on March 28, 2026. Additionally, the resignation of Mr. Manohar Lalge as President - Research and Development, and the appointment of Mr. Jatin Gajjar as Chief Technology Officer and Senior Management Personnel, both effective March 17, 2026, were also mentioned.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.